Marie Skłodowska-Curie Action
Innovative Training Networks (ITN)
2016-2020

Beactica 572724AB was Beactica AB was founded in 2006 based on research carried out at Uppsala University in collaboration with pharma and biotech industries. The company has developed proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. The focus is on how molecular interaction analysis and structural information can improve and advance the development of high quality, small molecule drug leads. This is combined with extensive expertise in fragment-based drug development, enzymology and medicinal chemistry. Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery. The company is currently utilising its drug discovery platform to build a pipeline of novel small molecule inhibitors to address unmet medical needs. The prioritized programmes focus on epigenetic regulation of various cancer forms through the selective and reversible inhibition of epigenetic enzymes. As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform and services in the area of SPR biosensor-based interaction analysis. 

 

Website link: Beactica
             

Staff involved in this project:

Dr. Per Källblad

PerKallbladDr. Per Källblad - Ph. D. in Drug design Per Källblad co-founded Beactica in 2006 and is Chief Executive Officer. He has significant international experience in interdisciplinary pharmaceutical research and has worked in collaborations with Aventis, Rhone-Poulenc Rorer, Roche, Cancer Research UK, Peakdale Molecular, Biovitrum and Tibotec. Per Källblad received his Ph.D. in Drug Design from Cambridge University, UK. He was a founding scientist at De Novo Pharmaceuticals Ltd (1999-2004), a Cambridge University spin-off that raised £17.5m in venture capital to bring a new drug discovery tool to market. At Medivir AB he worked with preclinical strategies for therapeutic targets on internal and external projects (2004-2006).

 

 

 

 

 

Dr. Konrad Koehler

Konrad KoehlerDr. Konrad Koehler– Ph.D. in Organic chemistry received his Ph.D. in organic chemistry at Emory University, Atlanta Georgia, and completed a N.I.H. funded postdoctoral fellowship at Sanford University, Palo Alto, California. Konrad Koehler has over 25 years’ experience in molecular modelling and drug discovery. He has worked at Searle R&D, Merck Italia, Solvay Pharmaceuticals GmbH, and Karo Bio AB where he has held a variety of positions including section head and project leader. Konrad Koehler was instrumental in establishing drug discovery collaborations with Abbott Laboratories, Bristol Meyers-Squibb, Merck & Co., and Pfizer, which resulted in four drug candidates that underwent clinical trials. Konrad Koehler joined Beactica in September 2015 as principal scientist.

 

 

 

 

 

 

 

 

 

Dr. Ulf Bremberg

Ulf BrembergDr. Ulf Bremberg – Ph. D. in Organic chemistry Ulf Bremberg joined Beactica as Chief Scientific Officer in 2015, with a background in medicinal chemistry and extensive experience of industrial pharmaceutical research, with emphasis on early discovery, patent strategies and oncology. Ulf has previously headed up the Lead Identification Facility at the Drug Discovery & Development Platform of SciLifeLab, a national pharmaceutical research infrastructure formed by a collaboration between Karolinska Institute, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Earlier positions include Chief Scientific Officer of OncoTargeting AB as well as positions as Chemistry Team Leader and Medicinal Chemist at Biovitrum and Pharmacia. Ulf did his post-doc at the Scripps Research Institute and holds a Ph.D. in Organic Chemistry from KTH Royal Institute of Technology.

  

 

Prof. Helena Danielson

Prof. Helena Danielson is Professor of Biochemistry at Uppsala University in Sweden since 2002. She is a specialist in enzyme-based drug disHelena Danielsoncovery and molecular recognition. Her basic education includes a Master of Science in Chemical Engineering at Lund University in 1982 followed by a Master of Science in Biochemistry, University of Rochester, Rochester, NY, USA in 1984, carried out as a Fulbright scholar. She returned to Sweden and obtained a Ph. D. in Biochemistry at Stockholm University in 1987. As a postdoc at Karolinska Institutet in Stockholm Helena Danielson started a research project on HIV protease as a drug target for AIDS, and has since then expanded her research to other enzymes and diseases, more recently also with an interest in membrane receptors, ion channels, protein-protein interactions, cell signaling and neurological function. Helena Danielson has focused on developing enzymology for drug discovery, and in particular SPR-biosensor based biomolecular interaction analysis for detailed studies of enzyme-inhibitor interactions and other important recognition processes in the life science area. Helena Danielson co-founded Beactica AB in 2006 and was Chief Scientific Officer until 2014. Now she is on the Board of Commissioners. She has held many administrative positions at Uppsala University, and was the Dean of the Faculty of Science and Technology 2011-2014. At present, she is head of the Department of Chemistry – BMC. 

 

 


Lijndik